AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
University of Michigan agrees to licensing of mammastatin technology.
2003 JUN 12 - (NewsRx.com & NewsRx.net) -- Genesis Bioventures, Inc., (GBI) announced that the University of Michigan has granted exclusive worldwide licensing rights to the company for diagnostic uses of the mammastatin technology.
Mammastatin is a protein that has been found in studies to be present in the blood of most healthy women and absent, or in low levels, in the blood of most breast cancer patients or women known to be at high risk for developing breast cancer.
Research has shown that measuring the level of mammastatin in serum samples may be a useful breast health assessment tool, particularly as it relates to risk of developing breast cancer. A recent peer-reviewed publication in the March 2003 issue of IVD (In Vitro Diagnostics) Technology describes the technology and study results in more detail.
The license agreement secures the independent technology rights for GBI and its sublicensee, Biomedical Diagnostics, LLC, (Biomedical), a wholly owned subsidiary of GBI. Biomedical previously established leadership in the use of biological measures to develop the only blood serum test currently ...
- Diagnostics Intelligence: GBI to push breast-cancer risk test after completing...
- News wire article from: Chemical Business Newsbase January 15, 2002 700+ words
...is a joint venture between GBI and Biotheraphies Inc of Ann Arbor, MI. GBI will be marketing Biomedical...Mammastatin Serum Assay (MSA) breast cancer diagnostics testing product...Laboratories of Salt Lake City, UT. GBI will also have a right for...
- Hollywood Producer to Film Documentary on GBI's Revolutionary Breast Cancer...
- Press release article from: PR Newswire October 24, 2002 700+ words
...documentary on GBI's Mammastatin...this proprietary breast cancer risk assessment...diagnosed with breast cancer, and emphasizes...Technology Director for GBI stated, "This...revolutionize how breast cancer risk is determined...
- GBI to Acquire 100% Ownership of Biomedical Diagnostics.
- Press release article from: PR Newswire August 21, 2001 700+ words
...Biomedical changes GBI's business structure...as a screen for breast cancer risk, is available...generational history of breast cancer, regardless of...have developed breast cancer or not. The transaction...cash, will give GBI 100% ownership...
- GBI Signs Montauk Financial Group as Investment Banker.
- Press release article from: PR Newswire February 27, 2002 700+ words
...in over 150 offices. GBI's Chairman and CEO...provide the financing for GBI in order to allow the...in the fight against breast cancer by introducing a simple...their risk of developing breast cancer years before existing...relationship should allow GBI the opportunity to ...
- GBI Acquires 100% Ownership of Biomedical Diagnostics.
- Press release article from: PR Newswire December 3, 2001 700+ words
...Genesis Bioventures, Inc. (GBI - formerly BioLabs, Inc.) today...recently introduced as a screen for breast cancer risk. The test is available through...ownership of Biomedical Diagnostics, GBI and its shareholders have now turned...
- Merger & acquisition report: Gen-Probe, Invitrogen complete buys; Corgenix in...
- News wire article from: Asia Africa Intelligence Wire September 24, 2003 700+ words
...Westminster, CO, and Genesis Bioventures Inc (GBI) of Surrey, BC, Canada, have decided...Both firms had been collaborating on a breast cancer risk testing product, dubbed mammastatin...complex reference laboratory testing tool. GBI also controls Prion Developmental Laboratories...
- Corgenix Medical (Westminster, Colorado) and Genesis Bioventures (GBI; Surrey,...
- Newspaper article from: The BBI Newsletter April 1, 2004 700+ words
...Medical (Westminster, Colorado) and Genesis Bioventures (GBI; Surrey, British Columbia) have signed a definitive merger...development and worldwide commercialization of Genesis' Mammastatin breast cancer diagnosis system (MSA), the further expansion of Corgenix...
- Genesis Bioventures (GBI: New York) reported completing a bridge financing...
- Newspaper article from: Diagnostics & Imaging Week April 1, 2004 700+ words
...bring operating revenues to GBI, a worldwide distribution network...only enhances the ability of GBI to move its products to market more rapidly, but allows GBI to grow its business through...being the MSA as a screen for breast cancer risk. Corgenix develops anti...
- Corgenix Medical (Westminster, Colorado) has signed a letter of intent to merge...
- Newspaper article from: The BBI Newsletter September 1, 2003 700+ words
...merge with Genesis Bioventures (GBI; Surrey, British Columbia...Mammastatin Serum Assay (MSA) for breast cancer risk assessment, and diagnostic...Genesis will issue 14 million GBI shares in exchange for 100...2004. The merger is subject to GBI advancing to Corgenix $500...
- GBI RFP released; contract award expected in 90 days. (Ground Based Interceptor...
- Newspaper article from: Defense Daily November 24, 1992 700+ words
GBI RFP RELEASED; CONTRACT AWARD EXPECTED IN 90...RFP) for the Ground Based Interceptor (GBI) element of the Strategic Defense Initiative...demonstrate and, with final authorization, deploy GBI for the NMD segment of the Global Protection...
Source: HighBeam Research, University of Michigan agrees to licensing of mammastatin technology.